Skip to main content
. 2009 Sep 14;101(1):167–172. doi: 10.1111/j.1349-7006.2009.01368.x

Figure 2.

Figure 2

 Effects of various inhibitors on epidermal growth factor receptor (EGFR) and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with MET amplification. (A) HCC827 cells and a gefitinib‐resistant clone with MET amplification (HCC827 GR5) were incubated for 12 h in the absence (control) or presence of gefitinib alone (1 μm), PHA‐665752 alone (1 μm), gefitinib and PHA‐665752 combined, PP1 (10 μm), or dasatinib (500 nm) in medium containing 10% serum. Cell lysates were then subjected to immunoblot analysis with antibodies to phosphorylated (p‐) or total forms of EGFR, MET, ErbB3, Src, Akt, and Erk. (B) HCC827 and HCC827 GR5 cells were incubated for 24 h in medium containing 10% serum, lysed, and subjected to immunoprecipitation (IP) with an antibody to Src. The resulting precipitates were subjected to immunoblot analysis with antibodies to EGFR, MET, ErbB3, and Src.